pp 1–10 | Cite as

MicroRNA-155 Mediates Obesity-Induced Renal Inflammation and Dysfunction

  • Chenfei Zheng
  • Ji Zhang
  • Xinxin Chen
  • Jianna Zhang
  • Xiaokai Ding
  • Xiaohan You
  • Lin Fan
  • Chaosheng ChenEmail author
  • Ying ZhouEmail author


Chronic inflammation is a major contributor to obesity-related renal damage. Recent studies have demonstrated that microRNA (miR)-155 is closely associated with hyperglycemia-induced nephropathy, but whether renal miR-155 participates in the inflammatory response and development of obesity-related nephropathy is unknown. In present study, we investigated the pathophysiological role of renal miR-155 in palmitic acid (PA)-treated endothelial cell and high-fat-diet (HFD)-fed mouse models by specific miR-155 sponge. Mice fed with HFD exhibited higher levels of renal miR-155, which positively correlated with urine microalbumin and blood urea nitrogen. In vitro study, mouse renal vascular endothelial cells stimulated with PA also showed higher miR-155 levels, accompanied with increased inflammatory response. Suppression of renal miR-155 effectively attenuated HFD-induced renal structural damages and dysfunction. MiR-155 sponge treatment also significantly decreased NF-κB signaling and downstream gene expression in vitro and in vivo. The obesity-increased macrophage infiltration and lipotoxicity was decreased in mouse kidney after miR-155 sponge treatment. Mechanistically, miR-155 directly targeted 3′-UTR of SHIP1/INPP5D and suppressed its expression in vitro and in vivo, whereas silence of SHIP1/INPP5D abolished the renal protective benefits of miR-155 sponge in obese mice. Taken together, present findings for the first time provided evidence for the potential role of miR-155 in obesity-related nephropathy and clarified that SHIP1/NF-κB signaling was a potential molecular mechanism.


obesity nephropathy miR-155 inflammation SHIP1/INPP5D 


Funding Information

This work was supported by Wenzhou Committee of Science and Technology of China (ZS2017008, Y20170055 and Y20180159), the Zhejiang Medical Science and Technology Research Fund Project of China (LY14H050006), the Guangdong Medical Science and Technology Research Fund Project of China (A2018042), the Guangzhou Science and Technology Project of China (20170420167), and Zhejiang Province Natural Science Foundation (LY16H150007).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Grundy, S.M. 2004. Obesity, metabolic syndrome, and cardiovascular disease. The Journal of Clinical Endocrinology and Metabolism 89: 2595–2600.CrossRefGoogle Scholar
  2. 2.
    Seidell, J.C. 2000. Obesity, insulin resistance and diabetes--a worldwide epidemic. The British Journal of Nutrition 83 (Suppl 1): S5–S8.Google Scholar
  3. 3.
    Maric, C., and J.E. Hall. 2011. Obesity, metabolic syndrome and diabetic nephropathy. Contributions to Nephrology 170: 28–35.CrossRefGoogle Scholar
  4. 4.
    Bayliss, G., L.A. Weinrauch, and J.A. D'Elia. 2012. Pathophysiology of obesity-related renal dysfunction contributes to diabetic nephropathy. Current Diabetes Reports 12: 440–446.CrossRefGoogle Scholar
  5. 5.
    Elmarakby, A.A., and J.C. Sullivan. 2012. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovascular Therapeutics 30: 49–59.CrossRefGoogle Scholar
  6. 6.
    Wada, J., and H. Makino. 2013. Inflammation and the pathogenesis of diabetic nephropathy. Clinical Science 124: 139–152.CrossRefGoogle Scholar
  7. 7.
    Lim, A.K., and G.H. Tesch. 2012. Inflammation in diabetic nephropathy. Mediators of Inflammation 2012: 146154.CrossRefGoogle Scholar
  8. 8.
    Lennon, R., D. Pons, M.A. Sabin, C. Wei, J.P. Shield, R.J. Coward, J.M. Tavare, P.W. Mathieson, M.A. Saleem, and G.I. Welsh. 2009. Saturated fatty acids induce insulin resistance in human podocytes: Implications for diabetic nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 24: 3288–3296.CrossRefGoogle Scholar
  9. 9.
    de Vries, A.P., P. Ruggenenti, X.Z. Ruan, M. Praga, J.M. Cruzado, I.M. Bajema, V.D. D'Agati, H.J. Lamb, D. Pongrac Barlovic, R. Hojs, M. Abbate, R. Rodriquez, C.E. Mogensen, E. Porrini, and ERA-EDTA Working Group Diabesity. 2014. Fatty kidney: Emerging role of ectopic lipid in obesity-related renal disease. The lancet Diabetes & endocrinology 2: 417–426.CrossRefGoogle Scholar
  10. 10.
    Zhang, M.Z., Y. Wang, P. Paueksakon, and R.C. Harris. 2014. Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. Diabetes 63: 2063–2072.CrossRefGoogle Scholar
  11. 11.
    Liu, G., Y. Sun, Z. Li, T. Song, H. Wang, Y. Zhang, and Z. Ge. 2008. Apoptosis induced by endoplasmic reticulum stress involved in diabetic kidney disease. Biochemical and Biophysical Research Communications 370: 651–656.CrossRefGoogle Scholar
  12. 12.
    Lu, Y.C., W.C. Yeh, and P.S. Ohashi. 2008. LPS/TLR4 signal transduction pathway. Cytokine 42: 145–151.CrossRefGoogle Scholar
  13. 13.
    Conner, E.M., and M.B. Grisham. 1996. Inflammation, free radicals, and antioxidants. Nutrition 12: 274–277.CrossRefGoogle Scholar
  14. 14.
    Fernandez-Sanchez, A., E. Madrigal-Santillan, M. Bautista, J. Esquivel-Soto, A. Morales-Gonzalez, C. Esquivel-Chirino, et al. 2011. Inflammation, oxidative stress, and obesity. International Journal of Molecular Sciences 12: 3117–3132.CrossRefGoogle Scholar
  15. 15.
    Utimura, R., C.K. Fujihara, A.L. Mattar, D.M. Malheiros, I.L. Noronha, and R. Zatz. 2003. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney International 63: 209–216.CrossRefGoogle Scholar
  16. 16.
    Zhang, Y., B. Chen, X.H. Hou, G.J. Guan, G. Liu, H.Y. Liu, et al. 2007. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats. Chinese Medical Journal 120: 988–995.CrossRefGoogle Scholar
  17. 17.
    Rodriguez-Iturbe, B., Y. Quiroz, A. Shahkarami, Z. Li, and N.D. Vaziri. 2005. Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat. Kidney International 68: 1041–1047.CrossRefGoogle Scholar
  18. 18.
    An, H., H. Xu, M. Zhang, J. Zhou, T. Feng, C. Qian, et al. 2005. Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism. Blood 105: 4685–4692.CrossRefGoogle Scholar
  19. 19.
    Conde, C., X. Rambout, M. Lebrun, A. Lecat, E. Di Valentin, F. Dequiedt, et al. 2012. The inositol phosphatase SHIP-1 inhibits NOD2-induced NF-kappaB activation by disturbing the interaction of XIAP with RIP2. PLoS One 7: e41005.CrossRefGoogle Scholar
  20. 20.
    Lau, N.C., L.P. Lim, E.G. Weinstein, and D.P. Bartel. 2001. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294: 858–862.CrossRefGoogle Scholar
  21. 21.
    Zhang, Z., H. Peng, J. Chen, X. Chen, F. Han, X. Xu, X. He, and N. Yan. 2009. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Letters 583: 2009–2014.CrossRefGoogle Scholar
  22. 22.
    Putta, S., L. Lanting, G. Sun, G. Lawson, M. Kato, and R. Natarajan. 2012. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. Journal of the American Society of Nephrology : JASN 23: 458–469.CrossRefGoogle Scholar
  23. 23.
    Wang, Q., Y. Wang, A.W. Minto, J. Wang, Q. Shi, X. Li, and R.J. Quigg. 2008. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology 22: 4126–4135.CrossRefGoogle Scholar
  24. 24.
    Lin, X., Y. You, J. Wang, Y. Qin, P. Huang, and F. Yang. 2015. MicroRNA-155 deficiency promotes nephrin acetylation and attenuates renal damage in hyperglycemia-induced nephropathy. Inflammation 38: 546–554.CrossRefGoogle Scholar
  25. 25.
    Wang, G., B.C. Kwan, F.M. Lai, K.M. Chow, P.K. Li, and C.C. Szeto. 2011. Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Disease Markers 30: 171–179.CrossRefGoogle Scholar
  26. 26.
    Wang, H., W. Peng, X. Shen, Y. Huang, X. Ouyang, and Y. Dai. 2012. Circulating levels of inflammation-associated miR-155 and endothelial-enriched miR-126 in patients with end-stage renal disease. Brazilian journal of medical and biological research =. Revista brasileira de pesquisas medicas e biologicas 45: 1308–1314.Google Scholar
  27. 27.
    Baeuerle, P.A., and V.R. Baichwal. 1997. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Advances in Immunology 65: 111–137.CrossRefGoogle Scholar
  28. 28.
    Nguyen, D., F. Ping, W. Mu, P. Hill, R.C. Atkins, and S.J. Chadban. 2006. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology 11: 226–231.CrossRefGoogle Scholar
  29. 29.
    O'Connell, R.M., A.A. Chaudhuri, D.S. Rao, and D. Baltimore. 2009. Inositol phosphatase SHIP1 is a primary target of miR-155. Proceedings of the National Academy of Sciences of the United States of America 106: 7113–7118.CrossRefGoogle Scholar
  30. 30.
    Kurowska-Stolarska, M., S. Alivernini, L.E. Ballantine, D.L. Asquith, N.L. Millar, D.S. Gilchrist, J. Reilly, M. Ierna, A.R. Fraser, B. Stolarski, C. McSharry, A.J. Hueber, D. Baxter, J. Hunter, S. Gay, F.Y. Liew, and I.B. McInnes. 2011. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proceedings of the National Academy of Sciences of the United States of America 108: 11193–11198.CrossRefGoogle Scholar
  31. 31.
    Jin, H.M., T.J. Kim, J.H. Choi, M.J. Kim, Y.N. Cho, K.I. Nam, S.J. Kee, J. Moon, S.Y. Choi, D.J. Park, S.S. Lee, and Y.W. Park. 2014. MicroRNA-155 as a proinflammatory regulator via SHIP-1 down-regulation in acute gouty arthritis. Arthritis Research & Therapy 16: R88.CrossRefGoogle Scholar
  32. 32.
    Awad, A.S., H. You, T. Gao, T.K. Cooper, S.A. Nedospasov, J. Vacher, P.F. Wilkinson, F.X. Farrell, and W. Brian Reeves. 2015. Macrophage-derived tumor necrosis factor-alpha mediates diabetic renal injury. Kidney International 88: 722–733.CrossRefGoogle Scholar
  33. 33.
    Klessens, C.Q.F., M. Zandbergen, R. Wolterbeek, J.A. Bruijn, T.J. Rabelink, I.M. Bajema, et al. 2017. Macrophages in diabetic nephropathy in patients with type 2 diabetes. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 32: 1322–1329.Google Scholar
  34. 34.
    O'Connell, R.M., K.D. Taganov, M.P. Boldin, G. Cheng, and D. Baltimore. 2007. MicroRNA-155 is induced during the macrophage inflammatory response. Proceedings of the National Academy of Sciences of the United States of America 104: 1604–1609.CrossRefGoogle Scholar
  35. 35.
    Vyas, P., and D. Vohora. 2017. Phosphoinositide-3-kinases as the novel therapeutic targets for the inflammatory diseases: Current and future perspectives. Current Drug Targets 18: 1622–1640.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of NephrologyThe First Affiliated Hospital of Wenzhou Medical UniversityWenzhouChina

Personalised recommendations